Journal of Reproduction & Infertility

Journal of Reproduction & Infertility

Serum Levels of CCN3 Protein in Iranian Women with Polycystic Ovary Syndrome

Authors
Akram Vatannejad 1
Fatima Zahraa Fouani 2
Reza Fadaei 3
Asma Kheirollahi 1
Soheila Ansaripour 4
Maryam Shabani Nashtaei 5
Nariman Moradi 6
Hossein Montakhab-Yeganeh 7
Faezeh Fattahi 8
Farah Jadidizadeh 8
1 Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
2 Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
3 Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
4 Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
5 Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran; Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
6 Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
7 Department of Biochemistry, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas,
8 Emergency Department, Shahid Fayazbakhsh Hospital, Tehran, Iran
Abstract
Background: Polycystic ovary syndrome (PCOS) is a heterogeneous condition that encompasses several cardiometabolic and endocrinological disorders. Studies have shown that its pathogenesis aligns with several underlying mechanisms associated with recurrent pregnancy loss (RPL). Cellular communication network (CCN)-3 protein is a well-studied adipokine involved in tumorigenesis, organogenesis, inflammation, fibrosis, and glucose metabolism. The purpose of the current study was to determine the association of CCN3 levels with a number of parameters involved in PCOS pathogenesis. Methods: This is a case-control study including 120 PCOS patients (60 cases with RPL; PCOS-RPL and 60 cases with infertility; PCOS-Inf and 60 healthy controls). Circulating levels of homocysteine and high-sensitivity C-reactive protein (hs-CRP), homocysteine, and CCN3 were measured using ELISA kits. Results: Circulating levels of CCN3 were significantly elevated in PCOS-RPL and PCOS-Inf subgroups when compared to the control group (7.61±3.03 and 6.85±2.54 vs. 3.12±0.82, p<0.001). Serum CCN3 positively correlated with fasting insulin and homeostatic model assessment of insulin resistance (HOMA-IR) in the control group (p<0.05) and PCOS group (p<0.001). Moreover, CCN3 was significantly associated with PCOS (OR 4.808, 95%CI [2.744-8.423], p<0.001). Conclusion: According the results of this study CCN3 may be involved in the pathogenesis of PCOS. However, future studies are needed to evaluate the possibility of utilizing CCN3 in the diagnosis and treatment of the disease.
Keywords
abortion
C
reactive protein
CCN3
homocysteine
Metabolic Syndrome
Nephroblastoma overexpressed protein
polycystic ovarian syndrome
  1. Villa J, Pratley RE. Adipose tissue dysfunction in polycystic ovary syndrome. Curr Diab Rep. 2011;11(3):179-84.
  2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223-36.
  3. Sam S, Tasali E. Role of obstructive sleep apnea in metabolic risk in PCOS. Curr Opin Endocr Metab Res. 2021;17:46-51.
  4. Nehir Aytan A, Bastu E, Demiral I, Bulut H, Dogan M, Buyru F. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecol Endocrinol. 2016;32(9):709-13.
  5. Tan BK, Chen J, Hu J, Amar O, Mattu HS, Adya R, et al. Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(12):E1891-900.
  6. Shanaki M, Moradi N, Fadaei R, Zandieh Z, Shabani P, Vatannejad A. Lower circulating levels of CTRP12 and CTRP13 in polycystic ovarian syndrome: irrespective of obesity. PloS One. 2018;13(12):e0208059
  7. Calan M, Alan M, Alarslan P, Unal Kocabas G, Bozkaya G, Acara AC, et al. Association of decreased C1q/tumor necrosis factor-related protein-5 levels with metabolic and hormonal disturbance in polycystic ovary syndrome. J Turk Ger Gynecol Assoc. 2019;20(2):89-96.
  8. Gözüküçük M, Yarcı Gürsoy A, Destegül E, Taşkın S, Şatıroğlu H. Adiponectin and leptin levels in normal weight women with polycystic ovary syndrome. Horm Mol Biol Clin Investig. 2020;41(4).
  9. Sadeghi A, Fadaei R, Moradi N, Fouani FZ, Roozbehkia M, Zandieh Z, et al. Circulating levels of C1q/TNF-alpha-related protein 6 (CTRP6) in polycystic ovary syndrome. IUBMB Life. 2020;72(7):1449-59.
  10. Fouani FZ, Fadaei R, Moradi N, Zandieh Z, Ansaripour S, Yekaninejad MS, et al. Circulating levels of meteorin-like protein in polycystic ovary syndrome: a case-control study. PLoS One. 2020;15(4):e0231943.
  11. Serazin V, Duval F, Wainer R, Ravel C, Vialard F, Molina-Gomes D, et al. Are leptin and adiponectin involved in recurrent pregnancy loss? J Obstet Gynaecol Res. 2018;44(6):1015-22.
  12. Dos Santos E, Serazin V, Morvan C, Torre A, Wainer R, de Mazancourt P, et al. Adiponectin and leptin systems in human endometrium during window of implantation. Fertil Steril. 2012;97(3): 771-8.e1.
  13. Kim HS, Nagalla SR, Oh Y, Wilson E, Roberts CT Jr, Rosenfeld RG. Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci USA. 1997;94 (24):12981-6.
  14. Perbal B. Nuclear localisation of NOVH protein: a potential role for NOV in the regulation of gene expression. Mol Pathol. 1999;52(2):84-91.
  15. Perbal B. Contribution of MAV-1-induced nephroblastoma to the study of genes involved in human Wilms' tumor development. Crit Rev Oncog. 1994;5(6):589-613.
  16. Sakamoto K, Yamaguchi S, Ando R, Miyawaki A, Kabasawa Y, Takagi M, et al. The nephroblastoma overexpressed gene (NOV/ccn3) protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway. J Biol Chem. 2002;277(33):29399-405.
  17. Li CL, Martinez V, He B, Lombet A, Perbal B. A role for CCN3 (NOV) in calcium signalling. Mol Pathol. 2002;55(4):250-61.
  18. Su BY, Cai WQ, Zhang CG, Su HC, Perbal B. A developmental study of novH gene expression in human central nervous system. C R Acad Sci III. 1998;321(11):883-92.
  19. Burren CP, Wilson EM, Hwa V, Oh Y, Rosenfeld RG. Binding properties and distribution of insulin-like growth factor binding protein-related protein 3 (IGFBP-rP3/NovH), an additional member of the IGFBP superfamily. J Clin Endocrinol Metab. 1999;84(3):1096-103.
  20. Gupta N, Wang H, McLeod TL, Naus CC, Kyurkchiev S, Advani S, et al. Inhibition of glioma cell growth and tumorigenic potential by CCN3 (NOV). Mol Pathol. 2001;54(5):293-9.
  21. Maillard M, Cadot B, Ball RY, Sethia K, Edwards DR, Perbal B, et al. Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol. 2001;54(4):275-80.
  22. Martinerie C, Gicquel C, Louvel A, Laurent M, Schofield PN, Le Bouc Y. Altered expression of novH is associated with human adrenocortical tumorigenesis. J Clin Endocrinol Metab. 2001;86(8):3929-40.
  23. Manara MC, Perbal B, Benini S, Strammiello R, Cerisano V, Perdichizzi S, et al. The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol. 2002;160(3):849-59.
  24. Yu C, Le AT, Yeger H, Perbal B, Alman BA. NOV (CCN3) regulation in the growth plate and CCN family member expression in cartilage neoplasia. J Pathol. 2003;201(4):609-15.
  25. Thibout H, Martinerie C, Créminon C, Godeau F, Boudou P, Le Bouc Y, et al. Characterization of human NOV in biological fluids: an enzyme immunoassay for the quantification of human NOV in sera from patients with diseases of the adrenal gland and of the nervous system. J Clin Endocrinol Metab. 2003;88(1):327-36.
  26. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE. Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer. 2004;11(4):781-91.
  27. Lafont J, Jacques C, Le Dreau G, Calhabeu F, Thibout H, Dubois C, et al. New target genes for NOV/CCN3 in chondrocytes: TGF-beta2 and type X collagen. J Bone Miner Res. 2005;20(12):2213-23.
  28. Giusti V, Scotlandi K. CCN proteins in the musculoskeletal system: current understanding and challenges in physiology and pathology. J Cell Commun Signal. 2021;15(4):545-66.
  29. Kubota S, Kawaki H, Perbal B, Kawata K, Hattori T, Nishida T. Cellular communication network factor 3 in cartilage development and maintenance. J Cell Commun Signal. 2021;15(4):533-43.
  30. Son S, Kim H, Lim H, Lee JH, Lee KM, Shin I. CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer. Cell Death Dis. 2023;14(2):81.
  31. Yan X, Yan W, Fu X, Xu Y, Zhu N, Qiu C, et al. Single nucleotide mutation changes the capability of CCN3 in osteosarcoma cell invasion and differentiation. Transl Oncol. 2022;24:101485.
  32. Li JY, Wang YD, Qi XY, Ran L, Hong T, Yang J, et al. Serum CCN3 levels are increased in type 2 diabetes mellitus and associated with obesity, insulin resistance and inflammation. Clin Chim Acta. 2019;494:52-7.
  33. Shi H, Zhang C, Pasupuleti V, Hu X, Prosdocimo DA, Wu W, et al. CCN3 Regulates Macrophage Foam Cell Formation and Atherosclerosis. Am J Pathol. 2017;187(6):1230-7.
  34. Martinerie C, Garcia M, Do TT, Antoine B, Moldes M, Dorothee G, et al. NOV/CCN3: a new adipocytokine involved in obesity-associated insulin resistance. Diabetes. 2016;65(9):2502-15.
  35. Cao J, Singh SP, McClung JA, Joseph G, Vanella L, Barbagallo I, et al. EET intervention on Wnt1, NOV, and HO-1 signaling prevents obesity-induced cardiomyopathy in obese mice. Am J Physiol Heart Circ Physiol. 2017;313(2):H368-80.
  36. Henrot P, Moisan F, Laurent P, Manicki P, Kaulanjan-Checkmodine P, Jolivel V, et al. Decreased CCN3 in systemic sclerosis endothelial cells contributes to impaired angiogenesis. J Invest Dermatol. 2020;140(7):1427-34.e5.
  37. Naughton M, Moffat J, Eleftheriadis G, de la Vega Gallardo N, Young A, Falconer J, et al. CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis. J Neuroinflammation. 2020;17(1):349.
  38. Wei Y, Peng L, Li Y, Zhang N, Shang K, Duan L, et al. Higher serum CCN3 is associated with disease activity and inflammatory markers in rheumatoid arthritis. J Immunol Res. 2020;2020:3891425.
  39. Weingarten JA, Bellner L, Peterson SJ, Zaw M, Chadha P, Singh SP, et al. The association of NOV/CCN3 with obstructive sleep apnea (OSA): preliminary evidence of a novel biomarker in OSA. Horm Mol Biol Clin Investig. 2017;31(2).
  40. Tu P, Xu Q, Zhou X, Villa-Roel N, Kumar S, Dong N, et al. Myeloid CCN3 protects against aortic valve calcification. Cell Commun Signal. 2023;21(1):14.
  41. Flinn MA, Alvarez-Argote S, Knas MC, Almeida VA, Paddock SJ, Zhou X, et al. Myofibroblast Ccn3 is regulated by Yap and Wwtr1 and contributes to adverse cardiac outcomes. Front Cardiovasc Med. 2023;10:1142612.
  42. Gellhaus A, Schmidt M, Dunk C, Lye SJ, Kimmig R, Winterhager E. Decreased expression of the angiogenic regulators CYR61 (CCN1) and NOV (CCN3) in human placenta is associated with pre-eclampsia. Mol Hum Reprod. 2006;12(6):389-99.
  43. Wagener J, Yang W, Kazuschke K, Winterhager E, Gellhaus A. CCN3 regulates proliferation and migration properties in Jeg3 trophoblast cells via ERK1/2, Akt and Notch signalling. Mol Hum Reprod. 2013;19(4):237-49.
  44. Hassani F, Oryan Sh, Eftekhari-Yazdi P, Bazrgar M, Moini A, Nasiri N, et al. Downregulation of extracellular matrix and cell adhesion molecules in cumulus cells of infertile polycystic ovary syndrome women with and without insulin resistance. Cell J. 2019;21(1):35-42.
  45. Sadeghi A, Fadaei R, Moradi N, Fouani FZ, Roozbehkia M, Zandieh Z, et al. Circulating levels of C1q/TNF‐α‐related protein 6 (CTRP6) in polycystic ovary syndrome. IUBMB Life. 2020;72(7):1449-59.
  46. Vatannejad A, Salimi F, Moradi N, Fouani FZ, Zandieh Z, Ansaripour S, et al. Evaluation of angiopoietin-like protein 3 (ANGPTL3) levels in polycystic ovary syndrome. Life Sci. 2020;263:118595.
  47. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
  48. Lee RM, Silver RM. Recurrent pregnancy loss: summary and clinical recommendations. Semin Reprod Med. 2000;18(4):433-40.
  49. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28 (7):412-9.
  50. Connolly A, Leblanc S, Baillargeon JP. Role of lipotoxicity and contribution of the renin-angiotensin system in the development of polycystic ovary syndrome. Int J Endocrinol. 2018;2018:4315413.
  51. Di Sarra D, Tosi F, Bonin C, Fiers T, Kaufman JM, Signori C, et al. Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism. J Clin Endocrinol Metab. 2013;98(6):2581-8.
  52. Shimoyama T, Hiraoka S, Takemoto M, Koshizaka M, Tokuyama H, Tokuyama T, et al. CCN3 inhibits neointimal hyperplasia through modulation of smooth muscle cell growth and migration. Arterioscler Thromb Vasc Biol. 2010;30(4):675-82.
  53. Ren J, Wang X, Parry SN, Yee C, Gorrell MD, McLennan SV, et al. Targeting CCN2 protects against progressive non-alcoholic steatohepatitis in a preclinical model induced by high-fat feeding and type 2 diabetes. J Cell Commun Signal. 2022;16(3):447-60.
  54. Paradis R, Lazar N, Antinozzi P, Perbal B, Buteau J. Nov/Ccn3, a novel transcriptional target of FoxO1, impairs pancreatic β-cell function. PLoS One. 2013;8(5):e64957.
  55. Pakradouni J, Le Goff W, Calmel C, Antoine B, Villard E, Frisdal E, et al. Plasma NOV/CCN3 levels are closely associated with obesity in patients with metabolic disorders. PLoS One. 2013;8(6):e66788.
  56. Smina TP, Rabeka M, Viswanathan V. Diabetic foot ulcer as a cause of significant decline in the renal function among south Indian population with type 2 diabetes: role of TGF-β1 and CCN family proteins. Int J Low Extrem Wounds. 2019;18(4):354-61.
  57. Riser BL, Najmabadi F, Garchow K, Barnes JL, Peterson DR, Sukowski EJ. Treatment with the matricellular protein CCN3 blocks and/or reverses fibrosis development in obesity with diabetic nephropathy. Am J Pathol. 2014;184(11):2908-21.
  58. Zheng T, Chen H. Resveratrol ameliorates the glucose uptake and lipid metabolism in gestational diabetes mellitus mice and insulin-resistant adipocytes via miR-23a-3p/ NOV axis. Mol Immunol. 2021;137:163-73.
  59. Wang H, Huang B, Hou A, Xue L, Wang B, Chen J, et al. High NOV/CCN3 expression during high-fat diet pregnancy in mice affects GLUT3 expression and the mTOR pathway. Am J Physiol Endocrinol Metab. 2021;320(4):E786-96.
  60. Sacerdoti D, Singh SP, Schragenheim J, Bellner L, Vanella L, Raffaele M, et al. Development of NASH in obese mice is confounded by adipose tissue increase in inflammatory NOV and oxidative stress. Int J Hepatol. 2018;2018:3484107.
  61. Abd El Kader T, Kubota S, Janune D, Nishida T, Hattori T, Aoyama E, et al. Anti-fibrotic effect of CCN3 accompanied by altered gene expression profile of the CCN family. J Cell Commun Signal. 2013;7(1):11-8.
  62. Akashi S, Nishida T, El-Seoudi A, Takigawa M, Iida S, Kubota S. Metabolic regulation of the CCN family genes by glycolysis in chondrocytes. J Cell Commun Signal. 2018;12(1):245-52.
  63. Escoté X, Gómez-Zorita S, López-Yoldi M, Milton-Laskibar I, Fernández-Quintela A, Martínez JA, et al. Role of omentin, vaspin, cardiotrophin-1, TWEAK and NOV/CCN3 in obesity and diabetes development. Int J Mol Sci. 2017;18(8):1770.
  64. Trepiana J, Gómez-Zorita S, Fernández-Quintela A, González M, Portillo MP. Effects of resveratrol and its analogue pterostilbene, on NOV/CCN3 adipokine in adipose tissue from rats fed a high-fat high-sucrose diet. J Physiol Biochem. 2019;75(3):275-83.
  65. Singh SP, McClung JA, Bellner L, Cao J, Waldman M, Schragenheim J, et al. CYP-450 epoxygenase derived epoxyeicosatrienoic acid contribute to reversal of heart failure in obesity-induced diabetic cardiomyopathy via PGC-1 α activation. Cardiovasc Pharm Open Access. 2018;7(1):233.
  66. Schragenheim J, Bellner L, Cao J, Singh SP, Bamshad D, McClung JA, et al. EET enhances renal function in obese mice resulting in restoration of HO-1-Mfn1/2 signaling, and decrease in hypertension through inhibition of sodium chloride co-transporter. Prostaglandins Other Lipid Mediat. 2018;137:30-9.
  67. Shen SH, Singh SP, Raffaele M, Waldman M, Hochhauser E, Ospino J, et al. Adipocyte-specific expression of PGC1α promotes adipocyte browning and alleviates obesity-induced metabolic dysfunction in an HO-1-dependent fashion. Antioxidants (Basel). 2022;11(6):1147.
  68. Waldman M, Singh SP, Shen HH, Alex R, Rezzani R, Favero G, et al. Silencing the adipocytokine NOV: a novel approach to reversing oxidative stress-induced cardiometabolic dysfunction. Cells. 2022;11(19):3060.
  69. Seow KM, Lin YH, Hwang JL, Wang PH, Ho LT, Lin YH, et al. Expression levels of haem oxygenase-1 in the omental adipose tissue and peripheral blood mononuclear cells of women with polycystic ovary syndrome. Hum Reprod. 2011;26(2):431-7.
  70. Gao H, Meng J, Xing H, Nie S, Xu M, Zhang S, et al. Association of heme oxygenase-1 with the risk of polycystic ovary syndrome in non-obese women. Hum Reprod. 2014;29(5):1058-66.
  71. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415-45.
  72. Maleedhu P, Vijayabhaskar M, Sharma SSB, Kodumuri PK. Status of homocysteine in polycystic ovary syndrome (PCOS). J Clin Diagn Res. 2014;8(2):31-3.
  73. Asanidze E, Kristesashvili J, Andguladze S. Correlation between levels of homocysteine, anti-mullerian hormone and insulin resistance in PCOS patients with with recurrent miscarriage. Georgian Med News. 2019(290):25-9.
  74. Wagner MM, Jukema JW, Hermes W, le Cessie S, de Groot CJM, Bakker JA, et al. Assessment of novel cardiovascular biomarkers in women with a history of recurrent miscarriage. Pregnancy Hypertens. 2018;11:129-35.
  75. Kular L, Pakradouni J, Kitabgi P, Laurent M, Martinerie C. The CCN family: a new class of inflammation modulators? Biochimie. 2011;93(3):377-88.
  76. Zhu HP, Huang HY, Wu DM, Dong N, Dong L, Chen CS, et al. Regulatory mechanism of NOV/CCN3 in the inflammation and apoptosis of lung epithelial alveolar cells upon lipopolysaccharide stimulation. Mol Med Rep. 2020;21(4):1872-80.
  77. Liu J, Ren Y, Kang L, Zhang L. Overexpression of CCN3 inhibits inflammation and progression of atherosclerosis in apolipoprotein E-deficient mice. PLoS One. 2014;9(4):e94912.
  78. Zhang C, van der Voort D, Shi H, Zhang R, Qing Y, Hiraoka S, et al. Matricellular protein CCN3 mitigates abdominal aortic aneurysm. J Clin Investig. 2016;126(4):1282-99.
  79. Bedore J, Sha W, McCann MR, Liu S, Leask A, Séguin CA. Impaired intervertebral disc development and premature disc degeneration in mice with notochord-specific deletion of CCN2. Arthritis Rheum. 2013;65(10):2634-44.
  80. Riser BL, Najmabadi F, Perbal B, Rambow JA, Riser ML, Sukowski E, et al. CCN3/CCN2 regulation and the fibrosis of diabetic renal disease. J Cell Commun Signal. 2010;4(1):39-50.
Journal of Reproduction & Infertility
Volume 26, Issue 2
Spring 2025
Pages 98-108